Kymera Investor Presentation Deck

KYMERA KYMERA Recent Accomplishments Dosed first patients in KT-474 Phase 2 clinical trials in Hidradenitis Suppurativa and Atopic Dermatitis • Resulted in combined $55m from Sanofi in development milestones Published KT-474 Phase 1 study results in Nature Medicine; first clinical publication in TPD Demonstrated initial KT-333 anti-tumor activity in Phase 1 clinical trial; results presented at ASH 2023 Demonstrated proof-of-mechanism in KT-253 and initial antitumor activity in first patient cohort without typical MDM2 hematologic toxicity Cash runway guidance into first half of 2026 ©2023 KYMERA THERAPEUTICS, INC. PAGE 4

View entire presentation